FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979766702> ?p ?o ?g. }

• W2979766702 endingPage "169" @default.
• W2979766702 startingPage "159" @default.
• W2979766702 abstract "Poor chemotherapy response remains a major treatment challenge for high-grade serous ovarian cancer (HGSC). Cancer stem cells are the major contributors to relapse and treatment failure as they can survive conventional therapy. Our objectives were to characterise stemness features in primary patient-derived cell lines, correlate stemness markers with clinical outcome and test the response of our cells to both conventional and exploratory drugs. Tissue and ascites samples, treatment-naive and/or after neoadjuvant chemotherapy, were prospectively collected. Primary cancer cells, cultured under conditions favouring either adherent or spheroid growth, were tested for stemness markers; the same markers were analysed in tissue and correlated with chemotherapy response and survival. Drug sensitivity and resistance testing was performed with 306 oncology compounds. Spheroid growth condition HGSC cells showed increased stemness marker expression (including aldehyde dehydrogenase isoform I; ALDH1A1) as compared with adherent growth condition cells, and increased resistance to platinum and taxane. A set of eight stemness markers separated treatment-naive tumours into two clusters and identified a distinct subgroup of HGSC with enriched stemness features. Expression of ALDH1A1, but not most other stemness markers, was increased after neoadjuvant chemotherapy and its expression in treatment-naive tumours correlated with chemoresistance and reduced survival. In drug sensitivity and resistance testing, five compounds, including two PI3K-mTOR inhibitors, demonstrated significant activity in both cell culture conditions. Thirteen compounds, including EGFR, PI3K-mTOR and aurora kinase inhibitors, were more toxic to spheroid cells than adherent cells. Our results identify stemness markers in HGSC that are associated with a decreased response to conventional chemotherapy and reduced survival if expressed by treatment-naive tumours. EGFR, mTOR-PI3K and aurora kinase inhibitors are candidates for targeting this cell population. © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd." @default.
• W2979766702 created "2019-10-18" @default.
• W2979766702 creator A5005455563 @default.
• W2979766702 creator A5017337687 @default.
• W2979766702 creator A5019974013 @default.
• W2979766702 creator A5030148031 @default.
• W2979766702 creator A5033102814 @default.
• W2979766702 creator A5043341222 @default.
• W2979766702 creator A5044104350 @default.
• W2979766702 creator A5053034632 @default.
• W2979766702 creator A5054936862 @default.
• W2979766702 creator A5056487284 @default.
• W2979766702 creator A5064249338 @default.
• W2979766702 creator A5067760174 @default.
• W2979766702 creator A5068244748 @default.
• W2979766702 creator A5071621068 @default.
• W2979766702 creator A5073812413 @default.
• W2979766702 creator A5089980412 @default.
• W2979766702 date "2019-12-03" @default.
• W2979766702 modified "2023-10-15" @default.
• W2979766702 title "ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhibitors" @default.
• W2979766702 cites W1448393732 @default.
• W2979766702 cites W1748709546 @default.
• W2979766702 cites W1978789429 @default.
• W2979766702 cites W1997338647 @default.
• W2979766702 cites W1997391502 @default.
• W2979766702 cites W2000744297 @default.
• W2979766702 cites W2001544973 @default.
• W2979766702 cites W2002783575 @default.
• W2979766702 cites W2016594516 @default.
• W2979766702 cites W2017975901 @default.
• W2979766702 cites W2019774245 @default.
• W2979766702 cites W2020131167 @default.
• W2979766702 cites W2023427658 @default.
• W2979766702 cites W2026862874 @default.
• W2979766702 cites W2035121417 @default.
• W2979766702 cites W2037931409 @default.
• W2979766702 cites W2038619046 @default.
• W2979766702 cites W2038873665 @default.
• W2979766702 cites W2043398720 @default.
• W2979766702 cites W2057673391 @default.
• W2979766702 cites W2063277203 @default.
• W2979766702 cites W2067067209 @default.
• W2979766702 cites W2081447858 @default.
• W2979766702 cites W2083264977 @default.
• W2979766702 cites W2090973422 @default.
• W2979766702 cites W2090982381 @default.
• W2979766702 cites W2091882385 @default.
• W2979766702 cites W2094454542 @default.
• W2979766702 cites W2102085111 @default.
• W2979766702 cites W2115517051 @default.
• W2979766702 cites W2121986702 @default.
• W2979766702 cites W2123696077 @default.
• W2979766702 cites W2126712477 @default.
• W2979766702 cites W2132063594 @default.
• W2979766702 cites W2137525633 @default.
• W2979766702 cites W2142046859 @default.
• W2979766702 cites W2148063353 @default.
• W2979766702 cites W2151050516 @default.
• W2979766702 cites W2162922734 @default.
• W2979766702 cites W2222529560 @default.
• W2979766702 cites W2398060177 @default.
• W2979766702 cites W2556912286 @default.
• W2979766702 cites W2586556497 @default.
• W2979766702 cites W2705345269 @default.
• W2979766702 cites W2749108901 @default.
• W2979766702 cites W2761383206 @default.
• W2979766702 cites W2765084883 @default.
• W2979766702 cites W2769882826 @default.
• W2979766702 cites W2801767045 @default.
• W2979766702 cites W2811339164 @default.
• W2979766702 cites W2862725350 @default.
• W2979766702 cites W2888480300 @default.
• W2979766702 doi "https://doi.org/10.1002/path.5356" @default.
• W2979766702 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31595974" @default.
• W2979766702 hasPublicationYear "2019" @default.
• W2979766702 type Work @default.
• W2979766702 sameAs 2979766702 @default.
• W2979766702 citedByCount "34" @default.
• W2979766702 countsByYear W29797667022019 @default.
• W2979766702 countsByYear W29797667022020 @default.
• W2979766702 countsByYear W29797667022021 @default.
• W2979766702 countsByYear W29797667022022 @default.
• W2979766702 countsByYear W29797667022023 @default.
• W2979766702 crossrefType "journal-article" @default.
• W2979766702 hasAuthorship W2979766702A5005455563 @default.
• W2979766702 hasAuthorship W2979766702A5017337687 @default.
• W2979766702 hasAuthorship W2979766702A5019974013 @default.
• W2979766702 hasAuthorship W2979766702A5030148031 @default.
• W2979766702 hasAuthorship W2979766702A5033102814 @default.
• W2979766702 hasAuthorship W2979766702A5043341222 @default.
• W2979766702 hasAuthorship W2979766702A5044104350 @default.
• W2979766702 hasAuthorship W2979766702A5053034632 @default.
• W2979766702 hasAuthorship W2979766702A5054936862 @default.
• W2979766702 hasAuthorship W2979766702A5056487284 @default.
• W2979766702 hasAuthorship W2979766702A5064249338 @default.
• W2979766702 hasAuthorship W2979766702A5067760174 @default.
• W2979766702 hasAuthorship W2979766702A5068244748 @default.

• next